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Abstract 
Protection against viral challenge with canine oral papillomavirus (COPV) was 
achieved by immunisation via particle-mediated DNA delivery (PMDD) of a 
plasmid encoding the COPV L1 gene to cutaneous and oral mucosal sites in 
beagle dogs.  The initial dose of approximately 9µg of DNA was followed by two 
booster doses at 6 week intervals.  A similar approach was used to vaccinate a 
control group of animals with plasmid DNA encoding the Hepatitis B virus S 
gene.  Following challenge at the oral mucosa with canine oral papillomavirus all 
animals vaccinated with the COPV L1 gene were protected against disease.   
However 5 of 6 animals in the control group developed COPV induced 
papillomas at the oral mucosa.  Both cell mediated lymphoproliferative and 
humoral antibody responses to the DNA vaccine were observed.  Our data 
indicate that PMDD of plasmid DNA can protect against mucosal challenge with 
papillomavirus.  
 
  Human papillomavirus (HPV) infections, especially those affecting the genital 
mucosae, are associated with significant morbidity and mortality. It is now clear from 
epidemiological and laboratory studies that infection with specific human 
papillomavirus (HPV) types, in particular HPV 16 and 18 and their relatives, is the 
major risk factor for the subsequent development of cervix cancer in women (1).  HPV 
DNA is found in more than 90% of all cervix cancers (13) and some reports suggest 
that all cervix cancers are HPV associated (28).  Cervical cancer is the second 
commonest cancer in women worldwide; in developing countries it is the commonest 
female cancer and has a high mortality rate. Immunological intervention by 
prophylactic vaccination is an attractive prospect and an effective immunisation strategy 
against these viruses would be a major development in health care for women, 
especially in the third world, with a significant effect in reducing health care costs in 
both the developed and undeveloped world.   
The extreme species specificity of the papillomaviruses together with the 
inability to generate usable amounts of infectious genital HPVs by in vitro culture has 
meant that animal models are essential for the development and testing of vaccines and 
anti-virals against these agents.  Three models are of value, the cotton tail rabbit 
papillomavirus (CRPV), bovine papillomavirus (BPV) and the canine oral 
papillomavirus  (COPV) [for review, see (23)].  In addition to its natural host, the wild 
cotton tail rabbit, CRPV infects domestic rabbits although the viral life cycle is usually 
incomplete in this species.  CRPV only infects haired skin and, in view of the extreme 
tissue tropism of the pvs, it is possible that the CRPV/domestic rabbit model may not 
accurately reflect the immunobiology of the mucosal viruses.  BPV-4 is a 
mucosatrophic virus infecting the oropharynx and oesophagus of cattle.  However there 
are difficulties in monitoring the incidence and progression of lesions in these sites and  
 
the specialised husbandry requirements of such large animals precludes their use by 
most experimenters.  
The canine oral papillomavirus (COPV) is good model for mucosatrophic pv 
infection [for review see (18)].  COPV infects domestic dogs and wild canine species on 
the oropharyngeal and conjunctival mucosae where it induces warts (and very rarely 
squamous cell carcinomas (3, 26, 29)).  The lesions are very similar to those induced by 
the low risk genital HPVs and contain large amounts of infectious virus.  After infection 
by abrasion of the mucosal surface, oral papillomas appear within 4-8 weeks, before 
regressing spontaneously a further 4-6 weeks later, after which the animals are immune 
to challenge with infectious virus (5).  The benign lesions rarely cause problems but 
occasional cases of non-regressing successive crops of warts have been noted (16).  The 
warts contain high levels of virus and therefore are an excellent source of infectious 
virus for experiments in vitro.  COPV provides the optimal model for pre-clinical and 
proof of principle studies for papillomavirus vaccines.  The dog, a well characterised 
laboratory species, can be immunised with the antigen of interest and challenged with 
high dose of infectious virus on the upper lip, an easily accessible and observable area.  
The development of lesions is highly reproducible both in terms of wart area and time 
providing clean readouts for vaccine efficacy.  There is a good range of canine 
immunological reagents and assays of both humoral and cell mediated response can be 
undertaken, providing fundamental data on the mode of action of the vaccine 
preparations.   
In natural papillomavirus infections in the cow, rabbit and dog antibodies to the 
major capsid protein L1 are protective (4, 14, 25); prophylactic vaccine development 
has therefore focussed on this antigen.  Prophylactic immunity can be induced in these 
animal models, with whole virus preparations (2) or virus like particles (VLPs) (6, 12,  
 
25)  generated by self assembly of recombinant L1 protein expressed in eukaryotic 
vectors; denatured L1 does not offer prophylactic protection in the dog (25) and rabbit 
(14).  HPV L1 VLP vaccines are in Phase I/II clinical trials (30)  but  VLP based 
vaccines are expensive and, in the long term, may prove unsuitable for use in third 
world countries.  DNA vaccines have features that make them attractive candidates 
when compared with protein based preparations.  Large scale production is simpler; 
DNA once dried has long term stability over a wide temperature range and recombinant 
expression vectors encoding the DNA sequence of the antigen are able to induce long 
term cellular and humoral immunity (7, 19) without the need to purify protein products 
and produce VLPs.  DNA can be delivered intra-muscularly (i.m.) by needle injection 
(27) or intra-cutaneously (i.c.) (20, 21) using the gene gun for particle-mediated DNA 
delivery (PMDD).  Each route induces both cellular and humoral immunity but PMDD 
provides a strong cellular and humoral response with 100-1000 fold lower DNA doses 
than the needle injection route (9, 21).  Both routes of vaccination with CRPV L1 DNA, 
albeit with high DNA inputs, have been shown to induce protective immunity in the 
rabbit model (8, 24) but proof of principle for cutaneous DNA vaccination against 
mucosal papillomavirus infections has not been provided to date.  In this report we 
show that immunisation of beagle dogs with low doses of COPV L1 DNA delivered by 
PMDD to the skin and oral mucosa elicits a modest systemic antibody and T cell 
lymphoproliferative immune response that completely protects against challenge with 
high doses of infectious COPV. 
   
MATERIALS AND METHODS 
  Expression Vectors.  The plasmid pCMV-L1 (Glaxo-Wellcome, Stevenage, 
Herts, UK.) contains the complete COPV L1 open reading frame (ORF) cloned into  
 
vector WRG7077 containing a CMV promoter (PowderJect Vaccines, Madison, 
Wisconsin, USA.).  The L1 gene was derived from pBR322.COPV (DKFZ 
Referenzzentrum für Humanpathogene Papillomviren, Heidelberg, Germany).  
Purified pCMV-SPORT-βgal (kind gift from Dr W Peh and Dr J Doorbar, NIMR, 
Mill Hill, London) contains the β-galactosidase gene under the control of the CMV 
promoter in a 7.8kb circular DNA plasmid.  Plasmid pCMV-HBV-S (PowderJect 
Vaccines, Madison, WI, USA.) contains the hepatitis B virus surface (HBV-S) antigen 
under the control of the CMV promoter. 
  Cassette Preparation.  Preparation of cassettes for PMDD was as follows: 
DNA was precipitated onto 2 µm diameter gold micro-particles (DeGussa Metals 
Group, South Plainfield, NJ, USA) in the presence of spermidine (Sigma Chemical 
Co., St Louis, MO, USA) and calcium chloride (Fujisawa, Inc., Melrose Park, IL, 
USA) as described previously (15).  The gold-DNA precipitate was washed and 
resuspended in 100% ethanol and 0.05 mg/ml polyvinylpyrrollidine (PVP, Sigma) 
then adsorbed onto the inner surface of Tefzel tubing (TFX Medical Inc., Jaffrey, NH, 
USA) by centrifugal force using a tube turner device (PowderJect Vaccines, Inc., 
Madison, WI. USA).  The Tefzel tubing was subsequently cut into 1.27 cm length 
cassettes and stored desiccated at 4°C until use.  Each cassette contained theoretical 
weight of 0.5 mg gold micro-particles coated with a total dose of 0.75 mg plasmid 
DNA, as assessed by spectrophotometric analysis of DNA eluted from selected 
cassettes (GeneQuant II, Pharmacia Biotech). 
  Optimisation of PMDD.  Preliminary trials were undertaken on fresh canine 
cadavers to establish the optimum pressure for delivery of gold particles to the 
epidermis.  Punch biopsies of 6mm were taken immediately after PMDD to cutaneous 
(caudal ventral abdomen) and mucosal (buccal mucosa of the upper lip) sites at  
 
various pressures.  Tissues were embedded in optimal cutting temperature compound 
(OCT, BDH) and frozen in isopentane (BDH) cooled to its freezing point in liquid 
nitrogen.  Sections were cut on a cryostat, stained routinely with haematoxylin and 
eosin, and examined by light microscopy.  Once the optimal pressure had been 
established using the cadaver material, the β-galactosidase reporter construct (pCMV-
SPORT-βgal) was used in vivo on one beagle dog to check that the delivery protocol 
resulted in protein expression in the target tissues.  After PMDD to the oral mucosa 
6mm punch biopsies were taken at 2 and 9 days for detection of β-galactosidase 
activity. 
  Detection of β-galactosidase Activity.  Tissues were embedded in optimal 
cutting temperature compound (OCT, BDH) and frozen in isopentane (BDH) cooled 
to its freezing point in liquid nitrogen.  Frozen tissue was stored at  -70 °C ready for 
cryostat sectioning.  10 µm sections were cut and air dried for at least 30 min.  The 
sections were fixed by immersion in 100% ethanol for 2 min then washed in PBS (3 x 
3 min.).  The slides were immersed in development solution (70 ml PBS, 10 ml 
50mM potassium ferricyanide, 10 ml 50mM potassium ferrocyanide, 4 ml 50mM 
magnesium chloride, 1 ml 1 % sodium deoxycholate, 2 ml 1% Nonidet P-40.  100 mg 
x-gal powder was dissolved in 2.5 ml dimethylsulphoxide and added just prior to use) 
at 37 °C for 2 hours.  After washing in PBS (3 x 3 min.), the sections were 
counterstained in Carazzi's haematoxylin (45 seconds) and mounted in aquamount 
(Gurr).  Negative control sections were from normal canine oral mucosa. 
  Detection of in vitro expression.  Within several hours of death, tissues from 
the tongue, ventral abdominal skin and buccal mucosa were collected from dogs 
euthanased at the Department of Clinical Veterinary Medicine.  Tissues were stored 
on ice.  Prior to DNA transfection, the tissues were removed from ice and placed on a  
 
3 cm thick piece of foam for support.  PMDD was used at 400 psi to bombard the 
tissues with pCMV-L1 or pCMV-SPORT-βGal DNA coated gold particles at sites 
marked by pin prick tattoos of Indian ink.  The tissues were then returned to ice and 
transported to the laboratory in transport medium (a 1:1 mixture of Earle's balanced 
salt solution and Dulbecco's phosphate-buffered saline).  In a laminar flow cabinet, 
successfully targeted areas of tissue were confirmed by the presence of a superficial 
gold deposit, and excised by 6 mm punch biopsy.  The biopsies were washed in 
several changes of sterile PBS and placed onto sterile metal grids supported by metal 
rings at the fluid/air interface of the culture medium (500 ml GMEM, with the 
following added by filter sterilisation: 50 ml foetal bovine serum, 5 ml kanamycin (10 
mg/ml), 125 µl amphotericin (5 mg/ml), 500 µl cholera toxin (10-7M in serum free 
medium), 250 µl hydrocortisone (1 mg/ml)).  The explants were incubated at 37°C, 
5% CO2.  Medium was refreshed every other day, and biopsies were harvested at 1, 3 
and 5 days after transfection.  As negative controls, non-transfected tissues were 
cultured in a similar manner. 
COPV DNA was detected by in situ hybridisation and COPV L1 protein was detected 
by immunohistochemistry as previously described (17) (figure 2). 
  RNA-RNA  in situ  hybridisation.  Digoxygenin labelled riboprobes were 
prepared as per manufacturers instructions (Roche Diagnostics, Welwyn-Garden-
City).  Sections on Vectabond-coated slides (Vector laboratories) were dewaxed and 
rehydrated washed in PBS (2 x 3 min.) and encircled with a silicone pen (DAKO).  
The tissues were fixed in 4% paraformaldehyde with 5mM MgCl2 in PBS for 5 min. 
and re-washed in PBS (2 x 3 min.).  After digestion in RNAse-free DNAse (15 U/ml) 
in 2 x SSC for 1 hour at 37 °C in a humid chamber, the sections were washed in PBS 
(2 x 3 min.) and digested in Protease K (50 µg/ml in Protease K buffer (0.02M Tris  
 
pH 7.4, 2mM CaCl2) for 15 min. at 37 °C.  Sections were then washed in PBS (2 x 3 
min.) and re-fixed as above for 5 min.  After a final wash in PBS (2 x 3 min.), the 
sections were dehydrated through graded ethanols (30, 50, 70, 90, and 100%, 30 
seconds each) and air dried.  The section was covered in RNA probe diluted 1:10 or 
greater in hybridisation buffer (2 x SSC (1 x SSC = 0.15M NaCl, 0.015M sodium 
citrate), 5% dextran sulphate, 0.2% Marvel (Premier Beverages), 50% deionised 
formamide), according to the labelling efficiency, coverslipped and sealed with cow 
gum (Cow Proofings Ltd.).  Slides were incubated overnight at 42 °C.   
The gum was removed with forceps, and the coverslips soaked off in 2 x SSC, 0.1% 
SDS.  Slides were washed at 55 °C in 2x SSC, 0.1% SDS for 5 min. then incubated in 
RNAaseA (2 mg/ml in 5xSSC) for 15 min. at 37 °C in a humid chamber.  Sections 
were washed in 0.1 x SSC, 0.04% SDS (2 x 20 min, 65 °C), before soaking in 
blocking buffer and developing.  Sections were counterstained in Carazzi's 
haematoxylin (30-45 seconds). 
  Vaccination Protocol.  All vaccinations and biopsies were performed under 
general anaesthesia.  Food was withdrawn from the animals by 18.00hrs on the 
evening prior to anaesthesia.  Animals were examined and weighed before 
premedication with acepromazine maleate (ACP, C-Vet, 2mg/ml) at 0.03mg/kg as a 
sedative, and buprenorphine hydrochloride (Vetergesic, Animalcare, 0.3mg/ml) at 
10µg/kg by intramuscular injection as an analgesic.  Anaesthesia was induced by 
intravenous sodium thiopentane (Thiovet, C-Vet, 2.5%) at approximately 10mg/kg to 
effect.  After endotracheal intubation (cuffed) anaesthesia was maintained to effect 
with halothane (Fluothane, Mallinckrodt Vetinary) and oxygen (2-3 x respiratory 
minute volume) using a T-piece with Jackson-Reece modification.  
 
Six beagles were vaccinated with the pCMV-L1 plasmid at 12 sites (total dose 
9µg DNA); three on each side of the buccal mucosa and three on each side of the 
caudal ventral abdominal midline.  Boosting vaccinations were repeated in an 
identical manner after 6 weeks.  After 12 weeks a second boost was given at six sites, 
three on each side of the buccal mucosa.  At the end of the immunisation schedule 
each dog had received a total of 27µg DNA.  The control group comprised of six 
beagle dogs and all were vaccinated with the HBV S plasmid in an identical manner 
to the L1 vaccinees i.e. one primary immunisation and two boosts, a total of 27µg 
HBV-S DNA.  All vaccinations were performed using the PowderJect XR1 device at 
a delivery pressure of 400psi. 
  Serum Collection from Beagles.  Blood samples were withdrawn aseptically 
from the cephalic vein under gentle manual restraint or under general anaesthesia if 
collection coincided with vaccination or challenge.  The samples were centrifuged 
(IEC Sentra-7) at 2,500g for 10 minutes, the serum aspirated, aliquoted and frozen at 
–70
oC for use in ELISA studies later. 
  ELISA.  Flexible PVC microplates were coated with 100ng per well of 
purified COPV particles or HBV S protein suspended in carbonate buffer, pH 9.6, at 
4°C overnight. The plates were washed with PBS/0.05% Tween 20 and blotted dry 
prior to the addition of 100 µl per well of PBS/Tween containing 2% w/v skimmed 
milk powder (ELISA diluent) and incubation at 37 °C for 30 min.  Following further 
washing, 50µl aliquots of individual serum dilutions, from a doubling series made for 
each dog serum sample, were added to duplicate wells of the coated plates. Negative 
controls received diluent alone. The plates were re-incubated at 37°C for 1.5 hours, 
washed again, and peroxidase-conjugated, rabbit anti-dog IgG (1/500, ICN 
Immunobiologicals) was added to all wells. Following incubation for a further 1.5  
 
hours and a final wash, the plates were developed using an s-phenylene 
diamine/peroxide substrate in urea buffer (Sigmafast). Colour development was 
stopped with 20% sulphuric acid and absorbance levels were read at 490nm using a 
Molecular Devices plate reader. 
  Isolation of Peripheral Blood Monocytes (PBMC).  10 ml of canine blood 
was collected into a universal tube containing 100 µl of 100 mg/ml EDTA and diluted 
with an equal volume of PBS/EDTA (5.38 ml 0.5M Disodium EDTA in 500 ml 1x 
PBS).  5 ml of diluted blood was layered on top of 5 ml Ficol-Paque (Pharmacia), 
than centrifuged in a Sorvall (RC-3B) for 45 min at room temperature, 1,500 g, with 
the brake turned off.  Cells from the interface were collected using a 1.0 ml Gilson 
pipette.  To this an equal volume of 2% RPMI (RPMI-1640 (Sigma) 25 mM HEPES 
and NaHCO3, 0.3g L-Glutamine, Penicillin/Streptomycin, 10
-5 M 2-Mercaptoethanol 
(Sigma), 2% Foetal Calf Serum (FCS) (Harlan)) was added and the cells pelleted at 
1,500 g for 5 min, re-suspended in 2% RPMI then centrifuged again.  Cells were then 
re-suspended with 5ml 10% RPMI (The same as 2% RPMI but with 10% FCS) and 
counted (with Tryphan blue 1:1). 
  Lymphoproliferative Assay.  Samples were arranged in triplicate, in a 96-
well round bottom tissue culture plate (Falcon).  All antigens were suspended in 100µl 
10% RPMI/well.  The antigens used were Concanavalin A to a final concentration of 
2.5µg/ml as a positive proliferating agent control, purified COPV particles at 10
-3 to 
10
-8 dilutions of 0.45µg L1 protein/µl stock, and negative control wells containing 
100µl of medium only.  1x10
5 PBMC/well suspended in 100 µl 10% RPMI were 
added to the plate containing the antigen.  The plates were then incubated for 5 days at 
37
oC, 5% CO2.  
3H-Thymidine at 1µCi/well was added on the 5
th day and the plates 
incubated for a further 6 hours.  The cells were then harvested (LKB Wallac 1295-001  
 
cell harvester) onto filtermats (Helis Bio) and read using LKB Wallac 1205 beta plate 
liquid scintillation counter.  The standard index (S.I.) was then calculated by taking 
the mean cpm of the triplicate samples (after addition of antigen) and dividing this 
figure by the mean cpm of the negative control samples (media only). 
  Viral Challenge.  Under general anaesthesia the mucosa of the upper lip was 
lightly scarified over an area approximately 5mm x 5mm, using the tip of a scalpel 
blade, until a light ooze of blood occurred.  A 10µl aliquot of purified COPV 
(approximately 45ng of COPV L1 protein) from a clinical case of oral papillomatosis 
(17) was applied to each site by pipette and allowed to absorb for a few minutes.  10 
sites were challenged in each dog, 5 on each side of the upper lip.  The sites of 
challenge did not co-localise with the sites of immunisation.  COPV virus was 
isolated and purified as described previously (17). 
 
RESULTS 
  β-Galactosidase Expression Study.  In order to determine the optimum 
pressure for delivery of gold particles into oral and cutaneous sites in the dog, a fresh 
canine cadaver was used to test different pressures for gold delivery.  Cryostat 
sections from biopsies taken immediately after the procedure showed that a pressure 
of 400 psi delivered gold particles into the epidermis, reaching the basal layer (data 
not shown).  This pressure was used subsequently in the in vivo work.  To establish 
whether the delivery technique and construct expression system were effective in 
vivo, a β-galactosidase reporter construct (pCMV-SPORT-βgal) was delivered by 
PMDD into canine oral mucosa.  β-galactosidase activity was detected in small 
amounts in the superficial layers of the oral mucosal epithelium in biopsies taken two 
days later, but not in those taken nine days later or in negative control samples.  Gold  
 
particles were seen in the epidermis at two days, but not nine days, although 
occasional gold particles remained in the underlying dermis at nine days (figure 1).  
  DNA Vaccination and Viral Challenge.  12 beagle dogs were vaccinated as 
described earlier. Delivery of DNA coated gold particles using the PowderJect XR1 
device was associated with the development of localised inflammation and 
haemorrhage, due to ballistic damage of the cutaneous blood vessels by the gold 
particles and/or helium exhaust blast, together perhaps with physically-induced (non-
specific) degranulation of cutaneous mast cells.  These reactions were rapid in onset, 
typically being noticeable within a few minutes of vaccine delivery.  These reactions 
were restricted to the sites of vaccination, and comprised focal, reddened, 
oedamatous, slightly raised swellings.  Some sites developed serocellular oozing and 
crusting after 1 to 2 days.  Biopsy from the dog used in the β-galactosidase study at 
two  days after vaccination confirmed the presence of a prominent cellular 
inflammation response, including numerous neutrophils.  All sites healed completely 
with no lasting adverse effects. 
All animals were boosted with the DNA vaccine at 6 and 12 weeks after and 
challenged at 15 weeks after primary vaccination with approximately 45ng of purified 
COPV particles per site as described above.  Weekly blood sampling occurred 
through out the experiment.  After viral challenge the sites were examined and 
photographed at weekly intervals.  None of the six dogs vaccinated with the COPV L1 
encoding plasmid developed papillomas at any of the challenge sites, 60 sites in total.  
Of the six control dogs five developed oral papillomatosis (figure 3).  Three of these 
developed prominent warts at each of the ten oral sites challenged (figure 4): two dogs 
developed smaller warts at the majority of sites.  No observable warts were detected 
on the one remaining animal in the control group, although ELISA data indicated that  
 
the animal seroconverted at the same time as the other members of the challenge 
group and achieved comparable anti-L1 antibody titres indicating that it had received 
a viral challenge and suggesting that it had undergone a sub clinical infection (figure 
5).   
  Induction of Humoral Antibody Response.  Sera from all 12 Beagles was 
analysed for antibody response to whole COPV virus or HBV S antigen.  All six 
beagles vaccinated with HBV S DNA were taken as controls and were numbered 1 to 
6.  The six beagles vaccinated with COPV L1 were numbered 7 to 12.  All animals 
from the L1 group (numbers 7-12) showed a specific anti COPV L1 antibody 
response to vaccination (figure 6).  This antibody response against COPV was 
associated with protection from the subsequent viral challenge.  The control group 
(numbers 1-6) however, showed no significant COPV L1 antibody response to COPV 
prior to viral challenge (figure 5).  This lack of anti-COPV antibody was associated 
with a susceptibility to subsequent viral challenge, as illustrated by papilloma 
formation at the challenge sites. 
Animals 9, 10, 11 and 12 in the L1 vaccine group all showed a similar 
response; a specific anti-L1 antibody response was elicited by the vaccinations.  The 
circulating antibody levels induced by the vaccine were then reduced after the animals 
were challenged, remaining stable at this lower level.  Animal number 7 showed a 
moderate level antibody response to vaccination, which was maintained for 
approximately one month after challenge.  Thereafter, the antibody titre rose to a 
maximum by 8 weeks post challenge and was maintained for at least a further month.  
The final animal dog 8 showed only a low anti-L1 antibody response to virus, this low 
response was maintained throughout the experiment did not alter on challenge and the 
animal was protected (figure 6).  
 
In the control group (animals 1-6) a specific anti-COPV L1 antibody response 
was elicited post viral challenge.  The antibody titre increased from 4 weeks post 
infection to a maximum at 8 weeks post infection, this titre then decreased and was 
maintained at the lower level for the duration of the experiment.  In animals 6, 3, and 
5 florid papilloma formation matched the antibody titre with maximum wart size and 
number at 8 weeks post challenge.  Animals 4 and 2 had warts of shorter duration and 
size but showed a similar antibody response and titre.  The final animal, number 1, did 
not have any observed papillomas but the onset, duration and extent of the anti-L1 
antibody response was similar to that of the other members of the group (figure 5).  It 
seems likely that this animal either had a sub clinical infection or a papilloma of short 
duration.  All of those animals in the control group tested for an antibody response 
against HBV S antigen showed a significant response after vaccination (figure 7).   
  In Vitro proliferative response of PBMC.  All PBMC showed a proliferative 
response to Con A as a positive control antigen, with an S.I. of up to 300.  All six 
beagles vaccinated with HBV S DNA were taken as controls.  These animals showed 
no significant proliferative response to COPV prior to challenge (figure 8).  Following 
challenge all control animals showed a specific proliferative response to COPV with 
an average S.I. of 3.7, which was statistically significant.  Four of the six beagles 
vaccinated with COPV L1 DNA showed a specific cellular proliferation in response 
to COPV with an S.I. of 2.2 to 3.4 after vaccination, the remaining 2 animals (1 and 2) 
showed only a minimal proliferative response before challenge (figure 8).  The 
average S.I. for the L1 group was a significant proliferation response of 1.9.  After 




The work described above shows that COPV L1 specific, humoral, 
prophylactic immunity can be elicited by intra cutaneous and mucosal immunisation 
with the COPV L1 gene on a CMV driven plasmid.  The vaccination protocol used 
resulted in complete protection for all animals at 60 of 60 sites challenged with 
purified COPV.  A total dose of less than 30µg of DNA in total, delivered in 3 doses 
of 9µg was sufficient to protect individuals against viral challenge.  This vaccine dose 
elicited not only anti L1 IgG antibodies recognising COPV virions but also a specific 
T lymphoproliferative response to COPV virions. 
  In the experiments described in this report, sera from all animals were 
analysed against whole virus rather than COPV VLPs.  This provided a cleaner 
readout in ELISA and ensured that the antibody response detected was directed 
predominantly against conformational epitopes found on native virions.  The anti-L1 
titres generated were modest, a phenomenon observed also with COPV L1 VLP 
vaccines (25).  The weak anti COPV response observed with the DNA vaccine does 
not appear to be a reflection of PMDD since the control animals vaccinated with HBV 
S encoded in an identical vector and vaccinated by identical routes generated high 
titres of anti HBV S antibody.  It is possible that this reflects the response to secreted 
HBV-S protein as opposed to intra-cellular COPV L1 protein.  Despite the modest L1 
serum antibody titres all animals were protected against mucosal challenge with high 
doses of COPV.  The control HBV S vaccinated beagles showed no significant 
antibody response to COPV prior to challenge illustrating the specificity of the 
response in the L1 vaccinees.  Following challenge the 6 control animals showed the 
expected response to infection with anti L1 IgG titres increasing until 8 weeks post 
challenge, then decreasing slowly and plateauing at a stable value.  This ELISA data  
 
illustrates the reproducibility of the challenge in this outbred population.  Three 
animals were highly susceptible to infection developing florid papillomas 5-6 weeks 
at all sites post challenge.  The papillomas reached 10-12mm in size and persisted for 
5-6 weeks before regressing completely.  Two animals had smaller papillomas of 
shorter duration appearing 6 weeks post challenge and one animal had no visible 
papillomas.  However that individual had the expected anti L1 IgG response, 
seroconverting at the same time as the other members of control group and reaching 
comparable titres.  It is possible that this animal had a small papilloma of short 
duration missed in the weekly examination of the oral cavity or alternatively it 
underwent a subclinical infection.  Vaccinees were progeny from the same sire/dam 
matings as the control group and all vaccinees were protected from viral challenge, no 
warts being detected in any animal. 
Effective prophylactic vaccination with “live” (5) or formalin inactivated (2, 
10) crude COPV wart extract has been shown previously and vaccination with COPV 
L1 VLPs has been shown to be highly effective (10, 25).  It is known that this 
prophylactic immunity is mediated by serum immunoglobulin and that these are 
neutralising antibodies recognising conformational determinants (11, 25). DNA 
vaccines encoding COPV antigens have not been previously described.  However a 
CRPV L1 DNA vaccine delivered i.m has been shown to induce protection in the 
rabbit (8) although the vaccine dose used was 100 times greater (1mg per dose) than 
that employed in the present study.  It is known, however, that PMDD induces a 
strong cellular and humoral response with 100-1000 fold lower doses of DNA when 
compared with i.m. injection (9, 22).  Protection in the rabbit was achieved with 
intracutaneous vaccination of CRPV L1 DNA using a dose of 90 µg in total (24) still 
10 times greater than that employed in the present study.  
 
DNA vaccines have many advantages when compared with protein or 
attenuated viral vaccines.  They are highly stable, easily administered and inexpensive 
to produce in large quantities.  After purification, super-coiled plasmids can be 
lyophilised for storage at room temperature for long periods whereas proteins are 
considerably less thermostable.  The manipulation of DNA vaccines is relatively 
straightforward: they can encode multiple antigens and potentially one could 
immunise against several papillomavirus types in one poly valent vaccine, a strategy 
which may well be necessary for an effective prophylactic vaccine against high risk 
genital HPV types.  Long term persistence of antigen expression from polynucleotide 
vaccines allows an enduring T cell response as well as establishment of 
immunological memory (20).  The data presented in this report are encouraging for 
the development of DNA vaccines for papillomavirus infections.  The results support 
the use of L1 as the target antigen for prophylactic immunisation and illustrate the 
viability of this mode of vaccination in a mucosal papillomavirus infection that 
closely mirrors human mucosal papillomavirus infections.   
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Fig. 1. In vivo trial of reporter b-gal construct 2 days after PMDD. Gold particles are seen 2 
days after PMDD (a), expression at this stage is confined to superficial epithelium (b). The 















Figure 2:  In vitro expression of COPV L1 construct after PMDD at 400 psi. Detection of 
COPV DNA by DNA in situ showed streaks of DNA shed from gold particles in the upper 
epithelium at day 1 (A). Detection of L1 RNA transcripts by RNA in situ hybridisation 
revealed occasional positive cells from day 1 (B). Immunohistochemistry for L1 protein 
using CAMVIR 1 showed a similar pattern of occasional positive cells, often associated with 








Fig. 3. Appearance of COPV induced papillomas. The number of papillomas and their 












Fig. 4. Chronological record of papilloma life cycle from first appearance 5 weeks post 
challenge (A) through mature wart 8 weeks post challenge (D) to full regression 10 weeks 

























Fig. 6. Graph illustrating serum IgG response to COPV in COPV L1 vaccinated animals. 
Data represented here is for sera diluted 1 in 320. To represents sera taken on Day 0, C_2 














Fig. 7. Graph illustrating IgG response to HBV-S antigen in HBV vaccinated animals. Data 
represented here is for sera diluted 1 in 320. To represents sera taken at Day 0 and Challenge 
represents sera taken on the day of challenge. 
 
 
Fig. 8. Graph showing animals’ average lymphoproliferative response to COPV pre challenge  
following vaccination and post challenge with native virus. The COPV L1 vaccinated group 
and the control HBV vaccinated group are both shown. 